Aarti Pharmalabs (NSE:AARTIPHARM) Other Current Assets: ₹1,635 Mil (As of Mar. 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
57 GF Score
Price ₹709.45
GF Value ₹643.46
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Other Current Assets?

Aarti Pharmalabs NSE:AARTIPHARM +0.92% 57 Other Current Assets is ₹1,635 Mil as of Mar. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 57/100 and a GF Value™ of ₹643.46 (Fairly Valued). The stock has 3 warning signs investors should review.

Aarti Pharmalabs's other current assets for the quarter that ended in Mar. 2026 was ₹1,635 Mil.

Aarti Pharmalabs's quarterly other current assets declined from Sep. 2025 (₹1,795 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,635Mil).

Aarti Pharmalabs's annual other current assets increased from Mar. 2024 (₹773 Mil) to Mar. 2025 (₹932 Mil) increased from Mar. 2025 (₹932 Mil) to Mar. 2026 (₹1,635 Mil).


Aarti Pharmalabs Other Current Assets Related Terms


Aarti Pharmalabs Other Current Assets Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Other Current Assets Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Assets
Get a 7-Day Free Trial 800.83 411.29 772.93 932.40 1,635.48

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 932.40 0.00 1,794.71 0.00 1,635.48
NSE:AARTIPHARM
57GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of ₹1,635 Mil mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Other Current Assets of ₹1,635 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Aarti Pharmalabs.
Is Aarti Pharmalabs' Other Current Assets too high?
Aarti Pharmalabs' current Other Current Assets is ₹1,635 Mil. Overall, Aarti Pharmalabs has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Other Current Assets compare to ZTS and UTHR?
Aarti Pharmalabs' Other Current Assets of ₹1,635 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Aarti Pharmalabs. Aarti Pharmalabs's current Other Current Assets is ₹1,635 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹643.46, compared to a current price of ₹709.45 — trading 10.3% above its estimated fair value. The current Other Current Assets is ₹1,635 Mil. Aarti Pharmalabs' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Other Current Assets is ₹1,635 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹709.45 is trading 10.3% above its estimated GF Value™ of ₹643.46. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Other Current Assets: ₹1,635 Mil
  • GF Value™: ₹643.46 vs. price of ₹709.45 (10.3% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
57GF Score

Get the complete analysis for NSE:AARTIPHARM

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹709.45
Price
₹643.46
GF Value